AOD-9604growth hormone's fat-burning tail — the obesity drug that didn't make it

Strong on safety, weak on proof.

AOD-9604 inverts the usual research-peptide pattern. Most gray-market peptides have hyped efficacy and thin safety data; AOD-9604 has the opposite — an unusually solid human safety/exposure record (six clinical trials, ~900 participants, no consistent IGF-1 rise, no glucose disruption) but a weak, ultimately failed efficacy case. Its largest Phase IIb obesity trial didn't reach significance, and development was terminated in 2007. It earned GRAS food status at ≤1 mg/day (not a drug approval), is unapproved as a drug with an FDA safety-risk listing, and is explicitly WADA-prohibited. A separate, small cartilage/osteoarthritis signal is its only other human data point.

Growth hormone's fat job, minus the rest.

Full growth hormone does many things — builds muscle, drives IGF-1, mobilizes fat, perturbs glucose. AOD-9604 was engineered from GH's C-terminal "lipolytic domain" to capture the fat-mobilizing part while leaving the IGF-1/glucose machinery alone. In rodent and ex-vivo adipose models it increases lipolysis, suppresses lipogenesis, and raises fat oxidation; in humans it reliably does *not* raise IGF-1 or disrupt glucose. The catch: the strong adipose effects in animals never translated into a reproducible human body-composition signal. The nodes below separate the well-supported "no IGF-1/glucose effect" (Grade B) from the preclinical adipose mechanism (Grade C/P).

Oral trials, IV exposure — and a lot of unvalidated injecting.

AOD-9604's dosing splits cleanly: the actual clinical trials used oral (mg/day) and IV (µg/kg single-dose) routes, while the popular subcutaneous/IM microgram dosing is practice-pattern/gray-market with no supporting efficacy trials. There is no approved protocol for any route, and the FDA flags compounded injectable AOD-9604 for immunogenicity/impurity concerns. The calculator below uses micrograms for injectable math (with the oral mg/day trial ranges shown separately) and validates arithmetic only — it is not a prescribing tool.

Combinations — mostly lifestyle and marketing.

The honest read on AOD-9604 combinations is that the only one with real human context is the boring one — diet and exercise, which were the backdrop of the obesity trials and make it impossible to cleanly attribute any fat loss to the peptide. The GLP-1 and "fat-oxidation supplement" pairings are theoretical or marketing-driven with no validated combination data. The one genuine combination signal is intra-articular AOD-9604 plus hyaluronic acid in the knee-OA study — a niche, procedural use. The hard limit is the GH-axis: don't stack it with full GH, IGF-1 analogs, or secretagogues in anyone with malignancy or unexplained IGF-1 elevation.

A real safety database — with real caveats.

AOD-9604's safety story is genuinely better-documented than most research peptides: oral and IV human studies generally reported tolerability, with no consistent IGF-1 rise or glucose disruption. But the caveats are real and the page states them plainly. Human studies recorded headache, GI complaints (diarrhea/flatulence), infections, and serious adverse events in longer trials — including cancers that investigators did not consider drug-related but where causality is uncertain. The FDA separately states it has identified serious adverse events possibly associated with AOD-9604 (causality unclear) and flags immunogenicity and peptide-impurity concerns for compounded product. "Well-studied for safety" is not "proven safe long-term."

Practical safety framework

Contraindications & cautions

A full trial program — that ended in "not enough".

AOD-9604 has something most research peptides lack: a real, sequential clinical program (the METAOD studies) plus published preclinical work. IV single-dose safety (METAOD001/002), oral single- and multiple-dose studies (003/004), a 300-subject Phase IIb showing an early weight-loss signal (005), and then the larger ~500-subject OPTIONS trial (006) that failed to show sufficient efficacy under intensive diet/exercise — after which development stopped. The preclinical adipose data (Wu 1993, Heffernan, Ng) are consistently positive in animals. The honest summary: stronger human exposure/safety than gray-market peptides, but the efficacy case never matured into an approvable drug.

AOD-9604 among the GH-axis agents.

AOD-9604 sits in the GH/IGF family but is the deliberate outlier: it was designed to strip away the GH-receptor/IGF-1 activity that the others rely on. That's the key contrast — somatropin (full GH) and tesamorelin (GHRH analog) work *through* the IGF-1 axis and are FDA-approved for specific indications; MK-677 is an oral secretagogue that raises GH/IGF-1; AOD-9604 deliberately avoids that axis and, partly as a result, never demonstrated enough efficacy to be approved. The table keeps the approval reality honest — only somatropin and tesamorelin are approved drugs, both for narrow indications.

Related peptides.

The same fragment, three depths.

Source register.

Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. AOD-9604 is unusual in that its firmest sources support safety/tolerability (Grade B — the human trial program, no IGF-1/glucose rise) and the negative efficacy finding (Grade B/D — the failed Phase IIb), while the positive mechanistic story is preclinical (Grade C/P). The cartilage/OA study is a single human signal (Grade B/C). Regulatory, identity, and anti-doping records are Grade D. No source supports drug-level efficacy — which is precisely why it isn't an approved drug.

More Metabolic peptides & tools.